Latest Information Update: 13 May 2003
At a glance
- Originator LEO Pharma
- Class Anti-inflammatories
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Dermatitis
Most Recent Events
- 13 May 2003 Discontinued - Phase-II for Dermatitis in Europe (unspecified route)